Genetically modified immune cells take on Hard-to-Treat cancers
NCT ID NCT02869217
First seen Dec 29, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This early-phase study tests a treatment called TBI-1301 for people with advanced solid tumors (like sarcoma, melanoma, or ovarian cancer) that have not responded to other therapies. The treatment uses a patient's own immune cells, which are genetically modified in a lab to better recognize and attack cancer cells. The main goal is to check the safety of this approach and find the right dose, with a small group of 22 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.